ALNY241220P145000
- 22.70
- 0.000.00%
Alnylam Pharmaceuticals Newsroom
J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Announces Target Price $272
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,309,853, According to a Recent SEC Filing
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
FDA Begins Review of Alnylam's SNDA for Expanded Amvuttra Use
Scotiabank Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $310
Evercore Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $280
Scotiabank Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $384
Alnylam Pharmaceuticals: Strategic Positioning and Growth Opportunities Reinforce Buy Rating Amidst Competitive ATTR-CM Market
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $275
Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro
Sector Update: Health Care Stocks Edge Higher Premarket Monday
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
Express News | Alnylam Pharmaceuticals Inc - Vutrisiran Shows Encouraging Safety and Tolerability
Express News | Alnylam Pharmaceuticals Inc - FDA Sets Pdufa Date for Vutrisiran on March 23, 2025
Express News | Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of Attr Amyloidosis With Cardiomyopathy
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $371
Alnylam Pharmaceuticals Price Target Maintained With a $296.00/Share by Piper Sandler
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study